002007 Stock Overview
A biopharmaceutical company, researches, develops, produces, and commercializes blood products, vaccines, and recombinant proteins in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Hualan Biological Engineering Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.85 |
| 52 Week High | CN¥22.27 |
| 52 Week Low | CN¥13.72 |
| Beta | 0.32 |
| 1 Month Change | -0.059% |
| 3 Month Change | -5.92% |
| 1 Year Change | -22.42% |
| 3 Year Change | -42.84% |
| 5 Year Change | -32.18% |
| Change since IPO | 1,533.16% |
Recent News & Updates
Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E
Dec 30
Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly
Nov 18Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate
Oct 07Recent updates
Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E
Dec 30Hualan Biological Engineering (SZSE:002007) Seems To Use Debt Quite Sensibly
Nov 18Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 36% Below Their Intrinsic Value Estimate
Oct 07Why Investors Shouldn't Be Surprised By Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E
Aug 22Hualan Biological Engineering Inc. (SZSE:002007) Shares Could Be 37% Below Their Intrinsic Value Estimate
Jun 26Hualan Biological Engineering's (SZSE:002007) Dividend Will Be CN¥0.30
Jun 09These 4 Measures Indicate That Hualan Biological Engineering (SZSE:002007) Is Using Debt Safely
Jun 07Lacklustre Performance Is Driving Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E
May 21Is Hualan Biological Engineering (SZSE:002007) Using Too Much Debt?
Feb 27Shareholder Returns
| 002007 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.9% | -0.8% | 1.0% |
| 1Y | -22.4% | -22.3% | 8.2% |
Return vs Industry: 002007 matched the CN Biotechs industry which returned -22.3% over the past year.
Return vs Market: 002007 underperformed the CN Market which returned 8.2% over the past year.
Price Volatility
| 002007 volatility | |
|---|---|
| 002007 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002007 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002007's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,709 | Bei Fan | www.hualanbio.com |
Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes blood products, vaccines, and recombinant proteins in China and internationally. The company offers blood products under the Hualan brand comprising human albumin, intravenous human immunoglobulin, human immunoglobulin, tetanus human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, human prothrombin complex, human coagulation factor VIII, human fibrinogen, freeze-dried human fibrin glue for surgery, and human fibrin adhesives. It also provides vaccines consisting of quadrivalent and split influenza virus vaccines, influenza A (H1N1) split vaccines, ACYW135 group meningococcal polysaccharide vaccines, recombinant hepatitis B vaccines, group A and C meningococcal polysaccharide vaccines, freeze-dried human rabies vaccines, adsorbed tetanus vaccines, and multiple vaccine products; and biological products.
Hualan Biological Engineering Inc. Fundamentals Summary
| 002007 fundamental statistics | |
|---|---|
| Market cap | CN¥31.55b |
| Earnings (TTM) | CN¥1.34b |
| Revenue (TTM) | CN¥4.92b |
23.0x
P/E Ratio6.3x
P/S RatioIs 002007 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002007 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.92b |
| Cost of Revenue | CN¥1.87b |
| Gross Profit | CN¥3.05b |
| Other Expenses | CN¥1.71b |
| Earnings | CN¥1.34b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.73 |
| Gross Margin | 61.92% |
| Net Profit Margin | 27.20% |
| Debt/Equity Ratio | 5.5% |
How did 002007 perform over the long term?
See historical performance and comparisonDividends
1.8%
Current Dividend Yield41%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 09:19 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hualan Biological Engineering Inc. is covered by 41 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ethan Cui | BofA Global Research |
| Min Luo | Central China Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |